Rate of sentinel lymph node visualization in fatty breasts:Tc-99m Tilmanocept versus Tc-99m filtered sulfur colloid. Maryam Shahrzad, MD; Valeria Moncayo, MD, John Malko, MD; R. K. Halkar, MD; Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Emory University, Atlanta, GA. [Poster] 2016 Society of Nuclear Medicine and Molecular Imaging Annual Meeting; June 2016.
Comparison of Post-injection Site Pain Between Technetium Sulfur Colloid and Technetium Tilmanocept in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy. Jonathan T. Unkart, Jennifer L. Baker, Ava Hosseini, Carl K. Hoh, Mark S. Wallac, David R. Vera, and Anne M. Wallace., Ann Surg Oncol published online 15 August 2015. [DOI 10.1245/s10434-015-4802-y]
γ-Tilmanocept, a New Radiopharmaceutical Tracer for Cancer Sentinel Lymph Nodes, Binds to the Mannose Receptor (CD206) Abul K. Azad, Murugesan V. S. Rajaram, Wendy L. Metz, Frederick O. Cope, Michael S. Blue, David R. Vera and Larry S. Schlesinger., J Immunol published online 22 July 2015 [DOI:10.4049/jimmunol.14020050]
In Vivo Localization & Potential for Therapeutic Targeting of Kaposi’s Sarcoma with a CD206-Localizing Agent. M.McGrath, R. Zhang, T. Maurer et.al. [Poster] 18th International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agent, July 2015.
Imaging and Therapeutic Potential for Kaposi’s Sarcoma in Non-Cutaneous Foci with a CD206-Localizing Agent. B. Abbruzzese, F. Cope, R. Zhang, T. Maurer, M. McGrath, et. al. [Poster] 18th International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agent, July 2015.
Kaposi’s Sarcoma (KS) is a Macrophage (MO) Tumor Resulting from a Fusion of CD206+MOs and Lymphatic Endothelium. F. Cope, R.Zhang, T. Maurer, B. Abbruzzese, M.McGrath, et.al. [Poster] 18th International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agent, July 2015.
[99mTc]Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-institutional Trial. A. Agrawal, F. Civantos, S. Lai et al., Ann Surg Oncol (FEB 2015) First Online. [DOI 10.1245/s10434-015-4382-x]
Comparison of [99mTc]Tilmanocept and Filtered [99mTc]Sulfur Colloid for Identification of SLNs in Breast Cancer Patients. A. Wallace et al., Ann Surg Oncol (2015) 22:40–45. [DOI 10.1245/s10434-014-3892-2]
Use of a Novel Receptor-Targeted (CD206) Radiotracer, 99mTc-Tilmanocept, and SPECT/CT for Sentinel Lymph Node Detection in Oral Cavity Squamous Cell Carcinoma Initial Institutional Report in an Ongoing Phase 3 Study. A. Marcinow et al., JAMA Otolaryngol Head Neck Surg (2013) 139(9):895-902. doi:10.1001/jamaoto.2013.4239.
Comparative Evaluation of [99mTc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials. A. Wallace et al., Ann Surg Oncol (2013) 20:2590–2599.
3-Year Recurrence and Survival Outcomes after Sentinel Lymph Node Biopsy with [99mTc]Tilmanocept in Clinically Node-Negative Breast Cancer and Melanoma Patients,S.P. Povoski et al., Poster, SSO 2014, 67th Society of Surgical Oncology Annual Cancer Symposium.
Combined Efficacy Analysis from Three Phase 3 Trials of [99mTc]tilmanocept for Sentinel Lymph Node Biopsy in cN0 Breast Cancer, Melanoma, and Head/Neck SCC, J. Davis et al.,Poster, SSO 2014, 67th Society of Surgical Oncology Annual Cancer Symposium.
Combined Analysis of Phase III Trials Evaluating [99mTc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma, V.K. Sondak et al., Ann Surg Oncol (2013) 20:680–688.
Preclinical Studies of [99mTc]DTPA-Mannosyl-Dextran, C.K. Hoh et al., Nuclear Medicine and Biology 30 (2003) 457–464.
A Synthetic Macromolecule for Sentinel Node Detection: 99mTc-DTPA-Mannosyl-Dextran, D. R. Vera et al., The Journal Of Nuclear Medicine, Vol. 42 No. 6, June 2001 951-959.
Detection of Gastric and Colonic Sentinel Nodes Through Endoscopic Administration of 99mTc-DTPA-Mannosyl-Dextran in Pigs, J. Mendez et al., The Journal Of Nuclear Medicine, Vol. 44 No. 10, October 2003 1677-1681.
[99mTc]MAG3-mannosyl-dextran: a receptor-binding radiopharmaceutical for sentinel node detection, D.R. Vera et al., Nuclear Medicine and Biology 28 (2001) 493–498.
Lymphoseek: A Molecular Radiopharmaceutical for Sentinel Node Detection, A.M. Wallace et al., Ann Surg Oncol, Vol. 10, No. 5, 2003 531-538.
Sentinel Lymph Node Mapping of the Colon and Stomach Using Lymphoseek in a Pig Model, S.J. Ellner et al., Annals of Surgical Oncology, 11(7)(2004)674–681.
Dose-dependent biodistribution of [99mTc]DTPA-mannosyl-dextran for breast cancer sentinel lymph node mapping, S.J. Ellner et al., Nuclear Medicine and Biology 30 (2003) 805–810.
NAV4694 (formerly AZD4694)
Head-to-Head Comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for b-Amyloid Imaging in Aging and Dementia: C. Rowe et al, J Nuc Med 4/10/13 doi:10.2967/jnumed.112.114785.
AZD4694 PET Quantification for the Assessment of Fibrillar Amyloid–β Deposition, K. Chen, et al, Poster Presentation, Human Amyloid Imaging Meeting (HAI) 2012
AZD4694 PET in the Assessment of Fibrillar Amyloid–β Deposition: Performance Characteristics, J. Langbaum, et al, Poster Presentation, Human Amyloid Imaging Meeting (HAI) 2012
Fluorescent CD206-targeted Manocept-Cy3 (Mano-Cy3) specifically localizes on macrophages (MPs) derived from rheumatoid arthritis (RA) patients' synovial fluid & is quantitatively greater than that from non-RA patients. W. Jarjour, et al, Poster Presentation, Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2014, June 2014
lntravenous administration (lV) of the CD206-targeted Manocept-Cy3 (Mano-Cy3) to mice with induced rheumatoid arthritis (RA) results in heterogeneous localization of Mano-Cy3 with strong specificity for RA-expressing joints. T. Rosol, et al, Poster Presentation, Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2014, June 2014
CD206-targeted Cy3-Manocept (Mano-Cy3) localizes in nearly all cells present in Kaposi's sarcoma representing an opportunity for dynamic imaging, local staging and a potential for visceral metastasis imaging. M. McGrath,et al, Poster Presentation, Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2014, June 2014
Nature Outlook–Medical Imaging, October 2013
Navidea Whitepaper: Innovations in receptor-targeted precision imaging at Navidea: diagnosis up close and personal Frederick Cope etal1, Abul Azad2, Murugesen Rajaram2, Larry Schlesinger2, Wael Jarjour2, Thomas Rosol2, Ramiro Toribio2, Michael McGrath3, Leanne Huysentruyt3, Rongzhen Zhang3 & Paige Bracci3, 1Navidea Biopharmaceuticals, Inc., 2Ohio State University, 3 University of California, San Francisco
The following articles all originally appeared in journals from the Nature Publishing Group, which retains full responsibility for their content.
Expression and Function of the Mannose Receptor CD206 on Epidermal Dendritic Cells in Inflammatory Skin Diseases Andreas Wollenberg, Mieke Mommaas, Tilmann Oppel, Eva-Maria Schottdorf, Sandra Günther & Martina Modere + et al. Journal of Investigative Dermatology 118, 327–334 (2002).
Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs Wolfgang A Weber, Johannes Czernin, Michael E Phelps and Harvey R Herschman. Nature Clinical Practice Oncology (2008) 5, 44-54
Recent insights into the pathogenesis of Kaposi's sarcoma K Fife and M Bower, British Journal of Cancer (1996) 73, 1317-1322.
Protective and pathogenic functions of macrophage subsets Peter J. Murray & Thomas A. Wynn, Nature Reviews Immunology 11, 723-737 (November 2011).
Macrophage death and defective inflammation resolution in atherosclerosis Ira Tabas, Nature Reviews Immunology 10, 36-46 (January 2010).
Illuminating emergent activity in the immune system by real-time imaging Matthew F Krummel, Nature Immunology Volume: 11, Pages:554–557 (2010).
Emerging optical and nuclear medicine imaging methods in rheumatoid arthritis James M. Mountz, Abass Alavi & John D. Mountz , Nature Reviews Rheumatology 8, 719-728 (December 2012)